You just read:

Post-Hoc Analyses from Pivotal Phase 3 REFLECT Trial of LENVIMA® (lenvatinib) in Unresectable Hepatocellular Carcinoma to be Presented at 2019 Gastrointestinal Cancers Symposium

News provided by

Eisai Inc.

Jan 14, 2019, 17:10 ET